Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study of Ex Vivo Expanded/Activated Gamma Delta T-cell Infusion Following Haploidentical Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide

NCT03533816 is registered in ClinicalTrials.gov with University of Kansas Medical Center as lead sponsor.

NCT NCT03533816
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03533816 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study of Ex Vivo Expanded/Activated Gamma Delta T-cell Infusion Following Haploidentical Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide
Lead sponsor
University of Kansas Medical Center
Phase
Phase 1
Overall status
Recruiting
Start date
January 31, 2020
Completion date
January 31, 2028
Enrollment
38 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphoblastic leukemia, acute myeloid leukemia, chronic myeloid leukemia, myelodysplastic syndromes